Keryx Biopharma (KERX) Misses Q2 EPS by 59c
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Financial Fact:
Basic and diluted net loss per common share: -0.39
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Basic and diluted net loss per common share: -0.39
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Keryx Biopharma (NASDAQ: KERX) reported Q2 EPS of ($0.77), $0.59 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $14.51 million.
Full year 2017 net U.S Auryxia product sales guidance increased to $62 to $66 million
For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
